Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Rebekah Lucero

Nurse Practitioner, Family Pocatello, ID Nurse Practitioner

NPI 1285295634 CMS profile 11152230

777 Hospital Way, Ste 101, Pocatello, ID 83201

Open in the dashboard

General payments

$6,778

134 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rebekah Lucero of Pocatello, ID is reported in the CMS Open Payments database as having received $6,778 across 134 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,217 57
2024 General $985 42
2023 General $470 29
2022 General $106 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rebekah Lucero
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Rebekah Lucero were reported at $5,217. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Rebekah Lucero Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $0 $124 $35–$379 $132
2022 $106 $141 $44–$430 $149
2023 $470 $154 $49–$476 $160
2024 $985 $165 $51–$504 $164
2025 $5,217 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Medtronic, Inc. $4,609 28 payments
  2. Pfizer Inc. $298 19 payments
  3. Novartis Pharmaceuticals Corporation $285 17 payments
  4. AbbVie, Inc. $213 14 payments
  5. Amgen Inc. $194 6 payments
  6. Lexicon Pharmaceuticals, Inc. $161 5 payments
  7. Impulse Dynamics (USA) Inc. $140 2 payments
  8. Kiniksa Pharmaceuticals International, plc $134 6 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $101 5 payments
  10. Kestra Medical Technology Services, Inc. $97 2 payments
  11. Other $546 30 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Travel and Lodging $3,503 12 payments
  2. Food and Beverage $3,275 122 payments
Products named General payments · program years 2022–2025
  1. SYMPLICITY G3 $1,569 12 payments
  2. LEQVIO $285 17 payments
  3. VYNDAQEL $254 17 payments
  4. LINQ II $217 2 payments
  5. UBRELVY $151 7 payments
  6. OPTIMIZER Cardiovascular Device $140 2 payments
  7. OPTIMIZER Cardiovascular Device $140 2 payments
  8. Arcalyst $134 6 payments
  9. REPATHA $108 3 payments
  10. Assure WCD $97 2 payments
  11. Other $1,175 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

4,012

Median for Nurse Practitioner: 389

Drug cost

$866,456

Median for Nurse Practitioner: $21,885

Branded share of claims

26%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Camzyos Mavacamten Brand 26 $213,901
Eliquis Apixaban Brand 189 $186,335
Repatha Sureclick Evolocumab Brand 139 $96,162
Jardiance Empagliflozin Brand 125 $92,409
Farxiga Dapagliflozin Propanediol Brand 96 $84,194
Entresto Sacubitril/Valsartan Brand 91 $81,796
Xarelto Rivaroxaban Brand 45 $53,043
Praluent Pen Alirocumab Brand 35 $17,687
Ezetimibe Generic 334 $5,378
Potassium Chloride Generic 181 $4,413

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$28,531

Medicare's payments for the services billed

Medicare patients

331

Average age 77

Services billed

591

157 women, 174 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 64%
Heart failure 54%
Arthritis 51%
Atrial fibrillation 46%
Diabetes 35%
Chronic kidney disease 35%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $134
$134 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $124
$124 — —
Repatha
  • Amgen Inc. $86
$86 139 —
VYNDAQEL
  • PFIZER INC. $85
$85 — —
Inpefa
  • Lexicon Pharmaceuticals, Inc. $66
$66 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

134 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record